Get the Stockscreener App
58.51
0.95%
-0.56
After Hours:
58.51
Biomarin Pharmaceutical Inc stock is traded at $58.51, with a volume of 1.18M.
It is down -0.95% in the last 24 hours and down -2.27% over the past month.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
See More
Previous Close:
$59.07
Open:
$59.19
24h Volume:
1.18M
Relative Volume:
0.49
Market Cap:
$11.25B
Revenue:
$2.95B
Net Income/Loss:
$523.88M
P/E Ratio:
21.75
EPS:
2.69
Net Cash Flow:
$620.18M
1W Performance:
-4.27%
1M Performance:
-2.27%
6M Performance:
+8.17%
1Y Performance:
-17.12%
1-Day Range:
$58.23
$60.71
1-Week Range:
$58.23
$61.97
52-Week Range:
$50.76
$73.18
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
58.51 | 11.36B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-20-26 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Nov-06-25 | Downgrade | Stifel | Buy → Hold |
| Sep-08-25 | Initiated | H.C. Wainwright | Neutral |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Feb-24-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-20-24 | Upgrade | Bernstein | Mkt Perform → Outperform |
| May-17-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-24 | Initiated | Evercore ISI | Outperform |
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
BioMarin Pharmaceutical (BMRN) Receives FDA Approval for Expanded Use of PALYNZIQ in Adolescents - Insider Monkey
Inflation Data: What is the target price for BioMarin Pharmaceutical Inc stock2026 Trends & Technical Pattern Based Signals - baoquankhu1.vn
EVP Of BioMarin Pharmaceutical Sold $996K In Stock - Benzinga
Jefferies Maintains Buy on BioMarin Pharmaceutical Inc. (BMRN) March 2026 - Meyka
BioMarin reports growth data for achondroplasia drug VOXZOGO - Investing.com South Africa
BioMarin reports growth data for achondroplasia drug VOXZOGO By Investing.com - Investing.com Nigeria
Jefferies reiterates Buy on BioMarin stock after DMD trial data - Investing.com
BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical - PR Newswire
First Trust Advisors LP Raises Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Capital Research Global Investors Purchases 2,145,717 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Dimensional Fund Advisors LP Purchases 671,566 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BofA cuts BioMarin stock price target to $85 on Voxzogo outlook - Investing.com UK
BMRN: Strong 2025 growth, major 2026 clinical milestones, and Amicus acquisition drive future outlook - TradingView
BMRN: Strong 2025 growth, Amicus acquisition, and key 2026 clinical milestones drive optimism - TradingView
Uniqure To Rally Around 92%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
BioMarin Pharmaceutical (NASDAQ:BMRN) Given New $85.00 Price Target at Bank of America - MarketBeat
PALYNZIQ Pediatric Label Expansion Under REMS Might Change The Case For Investing In BioMarin (BMRN) - simplywall.st
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz - Benzinga
BioMarin Pharmaceutical Inc. $BMRN Shares Bought by Korea Investment CORP - MarketBeat
Leerink Maintains Market Perform on BioMarin (BMRN) March 09, 2026 - Meyka
Leerink Partners reiterates Market Perform on BioMarin stock at $62 By Investing.com - Investing.com Australia
Leerink Partners reiterates Market Perform on BioMarin stock at $62 - Investing.com
Are Options Traders Aware of Insights on BMRN Stock That We Might Not Know? - Bitget
Do Options Traders Know Something About BMRN Stock We Don't? - Yahoo Finance
Earnings Beat: Is BioMarin Pharmaceutical Inc stock a value trapStop Loss & Technical Confirmation Trade Alerts - baoquankhu1.vn
BMRN: Strong 2025 growth, major pipeline milestones, and Amicus acquisition set to drive future value - TradingView
BMRN: Strong 2025 growth, robust pipeline, and Amicus acquisition set stage for future expansion - TradingView
WINTON GROUP Ltd Has $6.69 Million Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. $BMRN Position Boosted by Vinva Investment Management Ltd - MarketBeat
Assessing BioMarin Pharmaceutical (BMRN) Valuation After FDA Expands PALYNZIQ Label For Pediatric PKU - Sahm
Rhenman & Partners Asset Management Boosts BioMarin Pharmaceutical Holdings - National Today
Rhenman & Partners Asset Management AB Has $10.11 Million Stock Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Crossmark Global Holdings Inc. Has $4.02 Million Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Why BioMarin Pharmaceutical Inc. stock could see breakout soonEarnings Performance Report & Stepwise Trade Signal Implementation - Naître et grandir
Fisher Asset Management LLC Has $1.72 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Details Strategy Refresh, Voxzogo Competition and 40% Margin Goal at TD Cowen Confab - MarketBeat
(BMRN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
FDA Extends Approval of PKU Drug to Include Adolescents - Medscape
Skeletal Dysplasia Market - GlobeNewswire Inc.
BioMarin Pharma: The Under-Two Strategy and New Market Ramps Shaping Voxzogo’s Next Chapter! - Smartkarma
Global Orphan Drugs Market is Anticipated to Cross USD 350 Billion by 2032 | DelveInsight - Bolsamania
BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients - AOL.com
Elo Mutual Pension Insurance Co Boosts BioMarin Pharmaceutical Holdings - National Today
Elo Mutual Pension Insurance Co Purchases 22,851 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Barclays raises BioMarin stock price target to $105 on acquisition By Investing.com - Investing.com UK
Amicus Therapeutics shareholders approve acquisition by BioMarin Pharmaceutical - Investing.com
Shareholders back Amicus (NASDAQ: FOLD) sale to BioMarin Pharmaceutical - Stock Titan
The kids are alright: Old drug from BioMarin scores key win in teensSan Francisco Business Times - The Business Journals
Barclays raises BioMarin stock price target to $105 on acquisition - Investing.com
Truist reiterates Buy on BioMarin stock amid new competition - Investing.com India
BioMarin Pharmaceutical Holdings Reduced by Rafferty Asset Management - National Today
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.48%
1.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):